How to Achieve GCP Requirements for Sample Documentation with FDA/EMA Oversight

Introduction: Why Sample Documentation is a Core GCP Responsibility

In clinical trials, accurate and timely documentation of biospecimen collection, handling, and disposition is essential for compliance with Good Clinical Practice (GCP) guidelines. The FDA and EMA have repeatedly emphasized that inadequate or inconsistent sample documentation can lead to data integrity concerns, protocol deviations, and regulatory action.

Sample documentation is subject to the same standards as clinical data and must be attributable, legible, contemporaneous, original, and accurate (ALCOA). This article outlines how sponsors and sites can ensure audit-ready sample documentation that aligns with FDA and EMA expectations.

Regulatory Expectations for Sample Documentation

According to ICH E6(R2), all sample-related records must be maintained in a way that enables reconstruction of the trial conduct. This includes:

• Date and time of sample collection
• Sample type and volume collected
• Collector identity and signature or initials
• Visit number and protocol ID linkage
• Conditions of sample storage and shipment
• Chain of custody across handlers

Core SOP Components for Sample Documentation

An FDA-compliant SOP must specify:

• Required data fields for all sample collection forms (electronic or paper)
• Use of pre-printed, version-controlled sample logbooks
• Instructions for correcting errors in handwritten forms (single-line strikethrough)
• Sample log reconciliation frequency and roles (e.g., CRA, Lab Technician)
• Integration of eSource and eTMF systems for sample data storage

Table: Required Sample Documentation Fields

Case Study: EMA Inspection Finding on Sample Record Inconsistencies

In a 2022 oncology trial, EMA inspectors noted that 30% of sample collection records were missing processing timestamps, and 12% of sample labels had discrepancies with the source logs. The root cause was traced to inconsistent use of eLogs and delayed data entry post-procedure.

CAPA Actions Included:

• Immediate retraining on contemporaneous documentation
• Migration to barcode-enabled eSource system
• Monitoring of data entry delays through timestamp audits
• Central lab instructed to reject unmatched samples and issue alerts

Best Practices for eSource and eTMF Integration

Digitizing sample logs enhances consistency and real-time traceability. Key recommendations include:

• Use audit-trailed eForms with dropdown menus to minimize input errors
• Restrict access to authorized personnel only
• Enable auto-filling of subject metadata from CTMS
• Time-stamp every action (collection, processing, shipment)
• Regular eTMF reconciliation between sample logs and courier manifests

Staff Training and Accountability

Training must emphasize that incomplete sample logs are protocol violations. Training logs must be signed and dated. Site initiation visits (SIVs) should include:

• Hands-on practice of filling sample logs (paper and electronic)
• Checklist of do’s and don’ts (e.g., never overwrite entries)
• Mock audit scenarios focusing on documentation gaps
• Responsibility matrix (e.g., technician enters data, PI verifies weekly)

External Reference

For more on global expectations for biological sample documentation, see the EU Clinical Trials Register and related GCP audit summaries.

Conclusion

Sample documentation is not a mere clerical task—it is a regulatory pillar of GCP compliance. By standardizing forms, integrating electronic systems, enforcing contemporaneous data entry, and aligning SOPs with protocol specifications, sponsors and sites can ensure robust sample documentation. This in turn safeguards data integrity, subject safety, and inspection readiness.